Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients.
Sokolenko AP, Moiseyenko FV, Iyevleva AG, Ivantsov AO, Dolmatov GD, Shelekhova KV, Gulo EV, Topal AX, Artemieva EV, Abduloeva NH, Rysev NA, Barsova DA, Levchenko NV, Volkov NM, Egorenkov VV, Moiseyenko VM, Imyanitov EN. Sokolenko AP, et al. Among authors: moiseyenko fv. Int J Mol Sci. 2023 Jan 18;24(3):1870. doi: 10.3390/ijms24031870. Int J Mol Sci. 2023. PMID: 36768191 Free PMC article.
Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer.
Moiseyenko FV, Kuligina ES, Zhabina AS, Belukhin SA, Laidus TA, Martianov AS, Zagorodnev KA, Sokolova TN, Chuinyshena SA, Kholmatov MM, Artemieva EV, Stepanova EO, Shuginova TN, Volkov NM, Yanus GA, Imyanitov EN. Moiseyenko FV, et al. Int J Clin Oncol. 2022 May;27(5):850-862. doi: 10.1007/s10147-022-02128-6. Epub 2022 Feb 16. Int J Clin Oncol. 2022. PMID: 35171360 Free PMC article.
Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
Moiseyenko FV, Moiseyenko VM, Aleksakhina SN, Chubenko VA, Volkov NM, Kozyreva KS, Kramchaninov MM, Zhuravlev AS, Shelekhova KV, Ivantsov AO, Venina AR, Preobrazhenskaya EV, Mitiushkina NV, Iyevleva AG, Imyanitov EN. Moiseyenko FV, et al. Oncol Res Treat. 2016;39(10):605-614. doi: 10.1159/000449024. Epub 2016 Sep 15. Oncol Res Treat. 2016. PMID: 27710972 Clinical Trial.
First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
Moiseyenko VM, Moiseyenko FV, Yanus GA, Kuligina ES, Sokolenko AP, Bizin IV, Kudriavtsev AA, Aleksakhina SN, Volkov NM, Chubenko VA, Kozyreva KS, Kramchaninov MM, Zhuravlev AS, Shelekhova KV, Pashkov DV, Ivantsov AO, Venina AR, Sokolova TN, Preobrazhenskaya EV, Mitiushkina NV, Togo AV, Iyevleva AG, Imyanitov EN. Moiseyenko VM, et al. Among authors: moiseyenko fv. Clin Drug Investig. 2018 Jun;38(6):553-562. doi: 10.1007/s40261-018-0629-1. Clin Drug Investig. 2018. PMID: 29470838
Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation.
Moiseyenko FV, Egorenkov VV, Kramchaninov MM, Artemieva EV, Aleksakhina SN, Holmatov MM, Moiseyenko VM, Imyanitov EN. Moiseyenko FV, et al. Case Rep Oncol. 2019 May 16;12(2):339-343. doi: 10.1159/000500481. eCollection 2019 May-Aug. Case Rep Oncol. 2019. PMID: 31182949 Free PMC article.
Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
Mitiushkina NV, Tiurin VI, Iyevleva AG, Kholmatov MM, Filippova EA, Moiseyenko FV, Levchenko NE, Sardaryan IS, Odintsova SV, Lozhkina AM, Volkov NM, Karaseva NA, Moiseyenko VM, Orlov SV, Imyanitov EN. Mitiushkina NV, et al. Among authors: moiseyenko fv. Biochimie. 2018 Nov;154:19-24. doi: 10.1016/j.biochi.2018.07.018. Epub 2018 Jul 30. Biochimie. 2018. PMID: 30071258
15 results